Roche Gets Atezolizumab Applications Rolling
This article was originally published in Scrip
Executive Summary
Roche Holding AG is behind Merck & Co. Inc. and Bristol-Myers Squibb Co. in the commercial PD-1/PD-L1 immunotherapy race, but the Swiss company says its answer in the drug class, atezolizumab, has now started out on the regulatory road to approval amid high hopes for its therapeutic potential.